Increased level of soluble B2M has been observed in the cerebral spinal fluid of patients with HIV-associated dementia [28], Parkinson’s diseases [29], and Alzheimer’s disease [30], as well as implicated in cognitive impairments related to chronic hemodialysis [31, 32]. Here, B2M is linked to early-onset autosomal dominant Alzheimer disease.